A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

NCT01454479 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Endometrial Cancer

Interventions

DRUG: Lapatinib and ixempra

Sponsor

Hung-Hsueh Chou

Collaborators

[object Object]
[object Object]